Clay Thorp, Director at PhaseBio Pharmaceuticals Inc (PHAS), bought 5,000 shares at $3.67 ($18K) on 2020-11-23, disclosed to the SEC on 2020-11-24.
Open-market purchase of $18k PHAS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.67 | 3,000 | $11K | 61.1% |
| 2 | $3.50 | 2,000 | $7K | 38.9% |
| Total | $3.60 avg | 5,000 | $18K | 100% |
| Filing → |
| CLSD | BUY | 2022-12-21 | $14K | — | Filing → |
| VIGL | BUY | 2022-05-17 | $165K | — | Filing → |
| VIGL | BUY | 2022-03-28 | $22K | — | Filing → |